36,446 Results

FDA approves Ontruzant biosimilar for all indications of Herceptin.- Samsung Bioepis + Merck Inc.

 Added 18 hours ago

Samsung Bioepis Co., Ltd. announced that the FDA has approved Ontruzant (trastuzumab-dttb), a biosimilar referencing Herceptin (trastuzumab), across all eligible...

Safety trial of IN.PACT Admiral drug-coated balloon shows no link to mortality in peripheral artery disease.- Medtronic

 Added 18 hours ago

Medtronic announced new data shared on the IN.PACT Admiral drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in...

Phase III clinical DETECT study of NexoBrid meets primary endpoint in burns treatment.- MediWound

 Added 18 hours ago

MediWound announced that it has met its primary and all secondary endpoints in its pivotal U.S. Phase III clinical study...

European Commission approves Blincyto to to include (Ph-) CD19 positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD).- Amgen

 Added 18 hours ago

Amgen announced that the European Commission (EC) has approved an expanded indication for Blincyto (blinatumomab) monotherapy to include adult patients...

European Commission approves Orkambi for the treatment of children with cystic fibrosis aged 2 to 5 years old who have two copies of the F508del mutation. - Vertex Pharma

 Added 1 day ago

Vertex Pharmaceuticals (Europe) Limited announced that the European Commission has granted approval of the label extension for Orkambi (lumacaftor/ivacaftor) for...

Clinical Practice Guidelines for the Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU (Devlin et al., 2018)

To update and expand the 2013 Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the ICU.

Phase III trial of Imbruvica + chemo fails to meet endpoint in pancreatic cancer.- AbbVie

 Added 3 days ago

AbbVie announced an update on the Phase III RESOLVE trial (PCYC-1137) of Imbruvica (ibrutinib) in combination with chemotherapy agents nab-paclitaxel...

FDA Advisory Committee recommends Evenity to treat osteoporosis- Amgen + UCB

 Added 3 days ago

Amgen and UCB announced strong support from the FDA Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval...

UK NICE recommends use of Verzenios in breast cancer.- Eli Lilly

 Added 3 days ago

The UK's NICE has recommended the use of Verzenios (abemaciclib), from Eli Lilly, for locally advanced or metastatic forms of...

Phase III REACH-2 study of Cyramza to treat AFP-High liver cancer is published in The Lancet Oncology. - Eli Lilly

 Added 3 days ago

Eli Lilly and Company announced that results from the global Phase III REACH-2 study of Cyramza (ramucirumab) as a single...

Load more